HopeStage
Back to all studies
CompletedNCT00215579

Long-acting risperidone for people with psychosis who miss oral medicines

About this titleRead the official source — NCT00215579
Medication studyAges 18–65United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
ButnerSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2004
Recruitment status
Completed
Enrollment listed in the registry
64
Sponsor
Duke University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00215579
Official title
Show the full official title

Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Butner

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Duke University, a university.

Did this study involve medication?

Yes. The study involved medication, including Depot Risperidone Microsphere (Consta).

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies